Europe Cervical Cancer Screening Market, Forecast 2022-2027, Industry Trends, Share, Growth, Outlooks, Impact of COVID-19, Company Analysis
Europe Cervical Cancer Screening Market is expected to be valued at US$ 10.7 Billion in 2027. Cervical cancer originates in the cervix cells, which is the lower section of the uterus that attaches to the vaginal canal. Cervical cancer is now one of the most common malignancies in women and one of the most typical causes of cancer death in Europe. As a result, cervical cancer screening is an essential aspect of a woman's routine health and can aid in cervical cancer prevention. Furthermore, many women are now opting for a cervical cancer screening test due to increased awareness. The European government is also playing a critical role by organizing free medical camps, health reimbursement, and awareness activities.
Europe Cervical Cancer Screening Market is estimated to expand with a CAGR of 3.3% during 2021-2027:
The European Cervical Cancer Screening Market has grown in recent years due to an increase in the number of patients diagnosed with cervical cancer and increased awareness about cervical cancer screening programs. In addition, the market is being boosted by the increased demand for technologically sophisticated diagnostic treatments for detecting cervical and vaginal malignancies. Furthermore, the growing demand for better cancer diagnostics and recent advancements in cancer diagnosis and therapy, novel specific antigen identification, and insights into cancer's genetic underpinning have all aided the market's growth. The expanding older population will also add fuel to this business, as their desire for further cancer assays and tests will increase, leading to future market growth in Europe.
Pap Smear Test and HPV DNA Test Population & Market:
Because of the high incidence and death rate of cervical cancer in Europe, there is a huge demand for unique and reliable early detection and therapeutic screening. Surprisingly, there are excellent screening procedures for detecting precancerous cervix lesions. We examined the Europe Cervical Cancer Screening Market in our analysis, including Pap Smear Test and HPV DNA Test Population and Market. Cervical cancer screening tests are divided into Pap tests and HPV testing.
Cells from the cervix are removed, stained, and evaluated for abnormalities during a Pap test. Pap tests are frequently used in women to confirm cervical cancer or to search for changes in cells that could lead to cervical cancer in the future. As a result of the failure of cytology-based screening programs in Europe, alternative approaches such as HPV testing have emerged.
HPV infection is determined in HPV test cells collected from the cervix. HPV tests are being used to extend screening intervals and boost coverage in high-risk populations, in addition to their excellent sensitivity. Furthermore, the demand expansion is projected to be aided by breakthrough testing technologies and services that increase screening rates.
By Country – Europe Cervical Cancer Test Market & Population Share Analysis:
The Europe Cervical Cancer Test Market & Population Share Analysis has been done for the United Kingdom, France, Germany, Italy, Spain, Sweden, Switzerland, Norway, and the Netherlands in our report. According to our research, Germany, the United Kingdom, and France are the top three nations in the European region performing very well in the Cervical Cancer Screening Market. The market in the nations mentioned above is likely to dominate, owing to raising awareness of cervical cancer among women and the availability of high-quality healthcare facilities. Furthermore, the market is expected to develop at a faster rate due to rising healthcare costs, government legislation, and healthcare institute attempts to raise awareness about cervical cancer.
Impacts of COVID-19 on Europe's Cervical Cancer Screening Industry:
The abrupt emergence of the COVID-19 pandemic initiated strict lockdown measures across Europe, causing Cervical Cancer Screening to be disrupted. Due to the coronavirus pandemic, cervical cancer screening in European countries has decreased to deficient levels. In the aftermath of COVID-19, most non-urgent cervical cancer appointments were canceled. However, with social distancing and vaccination programs in the European region, the market returned to normal. In 2021, the Europe Cervical Cancer Screening Market was valued at US$ 8.8 Billion, according to Renub Research.
Renub Research report titled “Europe Cervical Cancer Screening Market & Forecast, By Test Population and Market (Pap smear and HPV DNA), Countries (United Kingdom, France, Germany, Italy, Spain, Sweden, Switzerland, Norway and Netherlands)” provides a complete analysis of Europe Cervical Cancer Screening Industry.
Cervical Cancer Diagnostics Market has been covered from 2 viewpoints:
1. Pap Smear Tests Market
2. HPV DNA Tests Market
Cervical Cancer Test Population has been covered from 2 viewpoints:
1. Pap Smear Test Population
2. HPV DNA Test Population
All the 9 Countries Studied in the Report are as Follows
1. United Kingdom
2. France
3. German
4. Ital
5. Spain
6. Sweden
7. Switzerland
8. Norway
9. Netherlands
- 1. Introduction
- 2. Research & Methodology
- 3. Executive Summary
- 4. Market Dynamics
- 4.1 Growth Drivers
- 4.2 Challenges
- 5. Europe Cervical Cancer Test (Screening) Analysis
- 5.1 Europe Cervical Cancer Test Population
- 5.1.1 Pap smear Test Population
- 5.1.2 HPV DNA Test Population
- 5.2 Europe Cervical Cancer Test (Screening) Market
- 5.2.1 Pap Smear Test Market
- 5.2.2 HPV DNA Test Market
- 6. Countries - Europe Cervical Cancer Test Market & Population Share Analysis
- 6.1 Europe Cervical Cancer Test Population Share
- 6.1.1 Pap Smear Population
- 6.1.2 HPV DNA Population
- 6.2 Europe Cervical Cancer Market Share
- 6.2.1 Pap Smear Market
- 6.2.2 HPV DNA Market
- 7. United Kingdom – Cervical Cancer Test Analysis
- 7.1 Population – Cervical Cancer Test (Screening)
- 7.1.1 Pap smear Test Population
- 7.1.2 HPV DNA Test Population
- 7.2 Market – Cervical Cancer Test (Screening)
- 7.2.1 Pap smear Test Market
- 7.2.2 HPV DNA Test Market
- 8. France – Cervical Cancer Test Analysis
- 8.1 Population – Cervical Cancer Test (Screening)
- 8.1.1 Pap smear Test Population
- 8.1.2 HPV DNA Test Population
- 8.2 Market – Cervical Cancer Test (Screening)
- 8.2.1 Pap Smear Test Market
- 8.2.2 HPV DNA Test Market
- 9. Germany – Cervical Cancer Test Analysis
- 9.1 Population – Cervical Cancer Test (Screening)
- 9.1.1 Pap smear Test Population
- 9.1.2 HPV DNA Test Population
- 9.2 Market – Cervical Cancer Test (Screening)
- 9.2.1 Pap Smear Test Market
- 9.2.2 HPV DNA Test Market
- 10. Italy – Cervical Cancer Test Analysis
- 10.1 Population – Cervical Cancer Test (Screening)
- 10.1.1 Pap smear Test Population
- 10.1.2 HPV DNA Test Population
- 10.2 Market – Cervical Cancer Test (Screening)
- 10.2.1 Pap Smear Test Market
- 10.2.2 HPV DNA Test Market
- 11. Spain – Cervical Cancer Test Analysis
- 11.1 Population – Cervical Cancer Test (Screening)
- 11.1.1 Pap smear Test Population
- 11.1.2 HPV DNA Test Population
- 11.2 Market – Cervical Cancer Test (Screening)
- 11.2.1 Pap Smear Test Market
- 11.2.2 HPV DNA Test Market
- 12. Sweden – Cervical Cancer Test Analysis
- 12.1 Population – Cervical Cancer Test (Screening)
- 12.1.1 Pap smear Test Population
- 12.1.2 HPV DNA Test Population
- 12.2 Market – Cervical Cancer Test (Screening)
- 12.2.1 Pap Smear Test Market
- 12.2.2 HPV DNA Test Market
- 13. Switzerland – Cervical Cancer Test Analysis
- 13.1 Population – Cervical Cancer Test (Screening)
- 13.1.1 Pap smear Test Population
- 13.1.2 HPV DNA Test Population
- 13.2 Market – Cervical Cancer Test (Screening)
- 13.2.1 Pap Smear Test Market
- 13.2.2 HPV DNA Test Market
- 14. Norway – Cervical Cancer Test Analysis
- 14.1 Population – Cervical Cancer Test (Screening)
- 14.1.1 Pap smear Test Population
- 14.1.2 HPV DNA Test Population
- 14.2 Market – Cervical Cancer Test (Screening)
- 14.2.1 Pap Smear Test Market
- 14.2.2 HPV DNA Test Market
- 15. Netherlands – Cervical Cancer Test Analysis
- 15.1 Population – Cervical Cancer Test (Screening)
- 15.1.1 Pap smear Test Population
- 15.1.2 HPV DNA Test Population
- 15.2 Market – Cervical Cancer Test (Screening)
- 15.2.1 Pap Smear Test Market
- 15.2.2 HPV DNA Test Market
- List Of Figures:
- Figure-01: Europe – Cervical Cancer Test (Screening) Population Volume (Million), 2017 – 2021
- Figure-02: Europe – Forecast for Cervical Cancer Test (Screening) Population Volume (Million), 2022 – 2027
- Figure-03: Europe – Pap Smear Test (Screening) Population Volume (Million), 2017 – 2021
- Figure-04: Europe – Forecast for Pap Smear Test (Screening) Population Volume (Million), 2022 – 2027
- Figure-05: Europe – HPV DNA Test (Screening) Population Volume (Million), 2017 – 2021
- Figure-06: Europe – Forecast for HPV DNA Test (Screening) Population Volume (Million), 2022 – 2027
- Figure-07: Europe – Pap Smear Test (Screening) Market (Million US
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook